Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.940
-0.135 (-4.39%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Evaxion Employees
Evaxion had 46 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
46
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$163,652
Profits / Employee
-$212,087
Market Cap
24.52M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| IGC Pharma | 70 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Jasper Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| VYNE Therapeutics | 10 |
EVAX News
- 3 days ago - Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO - TheFly
- 3 days ago - Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 - GlobeNewsWire
- 8 days ago - Evaxion Biotech presents new data on EVX-V1 - TheFly
- 8 days ago - Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewsWire
- 19 days ago - Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop - GlobeNewsWire
- 5 weeks ago - Evaxion receives Prix Galien UK Award for Best digital health solution - GlobeNewsWire
- 5 weeks ago - Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewsWire
- 2 months ago - Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress - GlobeNewsWire